BMO Capital Markets set a $38.00 target price on AstraZeneca (NYSE:AZN) in a research note issued to investors on Wednesday, January 10th. The brokerage currently has a buy rating on the stock.
AZN has been the subject of several other reports. Zacks Investment Research raised shares of AstraZeneca from a sell rating to a hold rating in a report on Wednesday, January 10th. JPMorgan Chase & Co. upgraded shares of AstraZeneca from a neutral rating to an overweight rating in a research report on Friday, December 29th. Leerink Swann lifted their price target on shares of AstraZeneca from $31.00 to $34.00 and gave the company a market perform rating in a report on Monday, October 23rd. Citigroup raised shares of AstraZeneca to a buy rating in a report on Wednesday, October 18th. Finally, Cowen reissued a hold rating and issued a $37.00 target price on shares of AstraZeneca in a report on Tuesday, October 17th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $34.48.
Shares of AstraZeneca (AZN) traded up $0.76 during mid-day trading on Wednesday, hitting $35.90. 7,474,899 shares of the company were exchanged, compared to its average volume of 3,330,000. AstraZeneca has a 12 month low of $26.98 and a 12 month high of $36.70. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. The stock has a market cap of $89,690.00, a PE ratio of 25.64, a P/E/G ratio of 2.72 and a beta of 0.74.
AstraZeneca (NYSE:AZN) last released its earnings results on Friday, February 2nd. The company reported $1.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.86. The company had revenue of $5.78 billion for the quarter, compared to analyst estimates of $5.49 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The firm’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.21 EPS. sell-side analysts anticipate that AstraZeneca will post 1.93 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in AZN. WFG Advisors LP raised its stake in AstraZeneca by 36.0% during the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after purchasing an additional 984 shares in the last quarter. Valeo Financial Advisors LLC purchased a new stake in AstraZeneca during the third quarter valued at $133,000. Quadrant Capital Group LLC raised its stake in AstraZeneca by 18.4% during the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after purchasing an additional 846 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in AstraZeneca during the third quarter valued at $184,000. Finally, FTB Advisors Inc. raised its stake in AstraZeneca by 3.2% during the second quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock valued at $197,000 after purchasing an additional 200 shares in the last quarter. 14.73% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “BMO Capital Markets Analysts Give AstraZeneca (NYSE:AZN) a $38.00 Price Target” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/02/astrazeneca-azn-given-a-38-00-price-target-by-bmo-capital-markets-analysts.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.